Inter- and intra-patient variability of raltegravir pharmacokinetics in HIV-1-infected subjectsDario Cattaneo, Emilio Clementi, Cristina Gervasoni et al.|Journal of Antimicrobial Chemotherapy|2011Cited by 58
Comparison of the <i>In Vivo</i> Pharmacokinetics and <i>In Vitro</i> Dissolution of Raltegravir in HIV Patients Receiving the Drug by Swallowing or by ChewingDario Cattaneo, Cristina Gervasoni, Matteo Cerea et al.|Antimicrobial Agents and Chemotherapy|2012Cited by 36
Metabolic and Kidney Disorders Correlate with High Atazanavir Concentrations in HIV-Infected Patients: Is It Time to Revise Atazanavir Dosages?Cristina Gervasoni, Dario Cattaneo, Paola Meraviglia et al.|PLoS ONE|2015Cited by 28
Co-administration of raltegravir reduces daily darunavir exposure in HIV-1 infected patientsDario Cattaneo, Emilio Clementi, Cristina Gervasoni et al.|Pharmacological Research|2011Cited by 21
Limited Sampling Strategies for the Estimation of Raltegravir Daily Exposure in HIV‐Infected PatientsDario Cattaneo, Emilio Clementi, Diego Ripamonti et al.|The Journal of Clinical Pharmacology|2011Cited by 19